Attached files
| file | filename |
|---|---|
| EX-99.1 - Lineage Cell Therapeutics, Inc. | ex99-1.htm |
| EX-31 - Lineage Cell Therapeutics, Inc. | ex31.htm |
| EX-23.2 - Lineage Cell Therapeutics, Inc. | ex23-2.htm |
| EX-23.1 - Lineage Cell Therapeutics, Inc. | ex23-1.htm |
| EX-21.1 - Lineage Cell Therapeutics, Inc. | ex21-1.htm |
| EX-10.38 - Lineage Cell Therapeutics, Inc. | ex10-38.htm |
| 10-K - Lineage Cell Therapeutics, Inc. | form10-k.htm |
Exhibit 32
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of BioTime, Inc. (the “Company”) for the year ended December 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Michael D. West, Co-Chief Executive Officer, Aditya Mohanty, Co-Chief Executive Officer, and Russell Skibsted, Chief Financial Officer of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: March 15, 2018
| /s/ Michael D. West | ||
| Michael D. West Ph.D. | ||
| Co-Chief Executive Officer | ||
| /s/ Aditya Mohanty | ||
| Aditya Mohanty | ||
| Co-Chief Executive Officer | ||
| /s/ Russell Skibsted | ||
| Russell Skibsted | ||
| Chief Financial Officer |